A detailed analysis of all articles submitted for publication to a leading medical journal over the last two years by the Editor-in-Chief saw that in most cases authors were unable to provide raw data to their articles when requested, raising doubts about the authenticity and credibility of the data being presented for publication. Although 97% … Read more
Electronic health records (EHRs) related administrative and regulatory burdens cause increased physician burnouts and leading to loss of productivity. A report by the DHHS’s Health IT office released this week lists ways to reduce the effort and time required to record information in EHRs, reduce the effort and time required to meet regulatory reporting requirements, … Read more
There is a video circulating on social media claiming that FDA allows significant amounts of filthy content in common foods such as cockroach parts, rat hair, and animal excreta in chocolate, mold and insect eggs in orange juice, insect larvae in corn, and so on. There is some truth in this statement, but it is … Read more
Last year, Vanda Pharmaceuticals sued FDA for putting its clinical trial on partial hold for lack of nonclinical data from dog studies. This week, a federal court ruled that FDA has the authority to ask for any additional data that FDA’s reviewers deem necessary to lift the clinical hold. The court further ruled that Vanda … Read more
As hospital and insurance systems monetize their patient databases by selling data to information companies like Google, they should share some of the financial rewards with the patients to avoid being accused of exploiting patient data for personal gains, according to ethicists as the University of Pennsylvania. Google and other information technology companies are acquiring … Read more
Patient presentations at FDA Advisory Committee meetings are very important for swaying the votes of reluctant jurors to vote in favor of approval. Almost none of the patient presentations are against the drug under review and all of them are paid for by the company who product is being debated by the Advisory Committee. A … Read more
Several recent reports have pointed out that while the industry has become increasingly compliant with submitting results of clinical trials to clinicaltrials.gov, the academic centers are way behind. A new reports highlights that it is primarily due to lack of resources and support available to academic centers for doing the same. Posting results to clinicaltrials.gov … Read more
Data collected from wearable devices contain several sources of “noise” that reduce the reliability of such data in support of clinical/medical claims. A report this week presents a summary of the various factors that contribute to erroneous results and reasonable tips to address them. While the use of wearable devices in clinical trials has almost … Read more
It has been a few years since the infamous Martin Shkreli was in the news. And we have another opportunity to thank him for exposing (unintentionally, of course!) some of the worst secret practices of the drug industry. This time Mr. Shkreli shows how companies can use non-disclosure agreements and exclusivity contracts to artificially keep … Read more
A Federal judge in California ruled that FDA’s interpretation of its own Guidance Documents regarding autologous cell therapy is faulty and hence subject to legal challenge. Specifically, the judge ripped through FDA interpretation of the “same surgical process” exemption for the regulation of Human Cellular and Tissue-based Products (HCT/P). The case in point was a … Read more
